Adiponectin as an anti-inflammatory factor

Clinica Chimica Acta

Volumn 380, Issue 1-2, 2007, Pages 24-30

  Ouchi, Noriyuki ^a   Walsh, Kenneth ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Anti inflammatory; Biomarker; Cardioprotection

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL TYPE; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE MARKER; DOWN REGULATION; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR ENDOTHELIUM;

ADIPONECTIN; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; HUMANS; INFLAMMATION MEDIATORS;

EID: 33947627537     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.01.026     Document Type: Review

References (106)

1. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003) 1785-1788
2. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., and Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14 (2003) 561-566
3. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005) 939-949
4. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 (1996) 10697-10703
5. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 (1996) 286-289
6. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
7. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
8. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
9. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
10. Kobashi C., Urakaze M., Kishida M., et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97 (2005) 1245-1252
11. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
12. Ouedraogo R., Wu X., Xu S.Q., et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 55 (2006) 1840-1846
13. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
14. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
15. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., Christian J.A., and Spurlock M.E. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316 (2004) 924-929
16. Yamaguchi N., Argueta J.G., Masuhiro Y., et al. Adiponectin inhibits toll-like receptor family-induced signaling. FEBS Lett 579 (2005) 6821-6826
17. Kumada M., Kihara S., Ouchi N., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 (2004) 2046-2049
18. Choi K.M., Ryu O.H., Lee K.W., et al. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75 (2007) 235-240
19. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
20. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278 (2003) 2461-2468
21. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 49 (2001) 554-560
22. Warley A., Powell J.M., and Skepper J.N. Capillary surface area is reduced and tissue thickness from capillaries to myocytes is increased in the left ventricle of streptozotocin-diabetic rats. Diabetologia 38 (1995) 413-421
23. Noon J.P., Walker B.R., Webb D.J., et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 99 (1997) 1873-1879
24. Yilmaz M.B., Biyikoglu S.F., Akin Y., Guray U., Kisacik H.L., and Korkmaz S. Obesity is associated with impaired coronary collateral vessel development. Int J Obes Relat Metab Disord 27 (2003) 1541-1545
25. Lind L., and Lithell H. Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J 125 (1993) 1494-1497
26. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., and Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97 (1996) 2601-2610
27. Al Suwaidi J., Higano S.T., Holmes Jr. D.R., Lennon R., and Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37 (2001) 1523-1528
28. Ouchi N., Kobayashi H., Kihara S., et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279 (2004) 1304-1309
29. Chen H., Montagnani M., Funahashi T., Shimomura I., and Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278 (2003) 45021-45026
30. Hattori Y., Suzuki M., Hattori S., and Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 46 (2003) 1543-1549
31. Motoshima H., Wu X., Mahadev K., and Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315 (2004) 264-271
32. Xi W., Satoh H., Kase H., Suzuki K., and Hattori Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 332 (2005) 200-205
33. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43 (1991) 109-142
34. Ohashi K., Kihara S., Ouchi N., et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47 (2006) 1108-1116
35. Ouchi N., Ohishi M., Kihara S., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42 (2003) 231-234
36. Shibata R., Ouchi N., Kihara S., Sato K., Funahashi T., and Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 279 (2004) 28670-28674
37. Kobayashi H., Ouchi N., Kihara S., et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94 (2004) e27-e31
38. Lin L.Y., Lin C.Y., Su T.C., and Liau C.S. Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett 574 (2004) 106-110
39. Shibata R., Sato K., Pimentel D.R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 (2005) 1096-1103
40. Kojima S., Funahashi T., Sakamoto T., et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89 (2003) 667
41. Bolli R., Shinmura K., Tang X.L., et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55 (2002) 506-519
42. Camitta M.G., Gabel S.A., Chulada P., et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 104 (2001) 2453-2458
43. Xiao C.Y., Yuhki K., Hara A., et al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109 (2004) 2462-2468
44. Hohlfeld T., Meyer-Kirchrath J., Vogel Y.C., and Schror K. Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart. J Mol Cell Cardiol 32 (2000) 285-296
45. Ilercil A., Devereux R.B., Roman M.J., et al. Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. Am Heart J 141 (2001) 992-998
46. Rutter M.K., Parise H., Benjamin E.J., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107 (2003) 448-454
47. Shibata R., Ouchi N., Ito M., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10 (2004) 1384-1389
48. Liao Y., Takashima S., Maeda N., et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67 (2005) 705-713
49. Fujioka D., Kawabata K., Saito Y., et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol 290 (2006) H2409-H2416
50. Tian R., Musi N., D'Agostino J., Hirshman M.F., and Goodyear L.J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104 (2001) 1664-1669
51. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (2002) 731-737
52. Nawrocki A.R., Rajala M.W., Tomas E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281 (2006) 2654-2660
53. Kubota N., Terauchi Y., Yamauchi T., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (2002) 25863-25866
54. Ma K., Cabrero A., Saha P.K., et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 277 (2002) 34658-34661
55. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
56. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98 (2001) 2005-2010
57. Tomas E., Tsao T.S., Saha A.K., et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 99 (2002) 16309-16313
58. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
59. Wu X., Motoshima H., Mahadev K., Stalker T.J., Scalia R., and Goldstein B.J. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52 (2003) 1355-1363
60. Satoh H., Nguyen M.T., Trujillo M., et al. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 54 (2005) 1304-1313
61. Combs T.P., Pajvani U.B., Berg A.H., et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145 (2004) 367-383
62. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
63. Ryo M., Nakamura T., Kihara S., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68 (2004) 975-981
64. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
65. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
66. Spranger J., Kroke A., Mohlig M., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 (2003) 226-228
67. Snehalatha C., Mukesh B., Simon M., Viswanathan V., Haffner S.M., and Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 26 (2003) 3226-3229
68. Choi K.M., Lee J., Lee K.W., et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 61 (2004) 75-80
69. Yamamoto Y., Hirose H., Saito I., Nishikai K., and Saruta T. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89 (2004) 87-90
70. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., and Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27 (2004) 2450-2457
71. Adamczak M., Wiecek A., Funahashi T., Chudek J., Kokot F., and Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16 (2003) 72-75
72. Iwashima Y., Katsuya T., Ishikawa K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 (2004) 1318-1323
73. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
74. Nakamura Y., Shimada K., Fukuda D., et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 90 (2004) 528-533
75. von Eynatten M., Schneider J.G., Humpert P.M., et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 47 (2006) 2124-2126
76. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
77. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
78. Schulze M.B., Shai I., Rimm E.B., Li T., Rifai N., and Hu F.B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 (2005) 534-539
79. Lindsay R.S., Resnick H.E., Zhu J., et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 25 (2005) e15-e16
80. Lawlor D.A., Davey Smith G., Ebrahim S., Thompson C., and Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90 (2005) 5677-5683
81. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
82. Ridker P.M. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92 (2003) 17K-22K
83. Laaksonen D.E., Niskanen L., Nyyssonen K., et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47 (2004) 1403-1410
84. Mendall M.A., Patel P., Ballam L., Strachan D., and Northfield T.C. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312 (1996) 1061-1065
85. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
86. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
87. Engeli S., Feldpausch M., Gorzelniak K., et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 52 (2003) 942-947
88. Mantzoros C.S., Li T., Manson J.E., Meigs J.B., and Hu F.B. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 4542-4548
89. Krakoff J., Funahashi T., Stehouwer C.D., et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26 (2003) 1745-1751
90. Matsubara M., Namioka K., and Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 148 (2003) 657-662
91. Matsushita K., Yatsuya H., Tamakoshi K., et al. Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men. Atherosclerosis 188 (2006) 184-189
92. von Eynatten M., Hamann A., Twardella D., Nawroth P.P., Brenner H., and Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 52 (2006) 853-859
93. Blake G.J., and Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ Res 89 (2001) 763-771
94. Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
95. Kappes A., and Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 32 (2000) 548-554
96. Fasshauer M., Kralisch S., Klier M., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301 (2003) 1045-1050
97. Ziccardi P., Nappo F., Giugliano G., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105 (2002) 804-809
98. Yang W.S., Lee W.J., Funahashi T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
99. Yu J.G., Javorschi S., Hevener A.L., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
100. Yang W.S., Jeng C.Y., Wu T.J., et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25 (2002) 376-380
101. Combs T.P., Wagner J.A., Berger J., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
102. Kubota N., Terauchi Y., Kubota T., et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281 (2006) 8748-8755
103. Marx N., Imhof A., Froehlich J., et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107 (2003) 1954-1957
104. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
105. Katsuki A., Sumida Y., Murata K., et al. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes Metab 2 (2000) 189-191
106. Wittchen F., Suckau L., Witt H., et al. Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets. J Mol Med (2006)